Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company offering an innovative therapeutic approach to “stasis and barrier applications.” This means improved time to cessation of bleeding (hemostasis) and the control of fluid leakage (sealant) during surgery and trauma care. Arch intends to transform the landscape of interventional healthcare with novel products to seal and protect tissue. Arch’s flagship product known as the AC5 Surgical Hemostatic Device™ is designed to elegantly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. In preclinical tests, AC5™ has been found to be simple, effective, and versatile.
If successful, the AC5 Surgical Hemostatic Device™ could make surgery faster and safer. This means better surgical outcomes for potentially everyone, including you.
CEO Terrence Norchi, MD - is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3 at 12:05 PM EST. - Click here to register for the live audio and HD video webcast.